Abstract: This invention relates to a novel process for synthesizing the product ibodutant shown in the figure below, consisting of a small number of high-yield steps involving reagents and solvents with low environmental impact, characterized by the coupling of two portions, compounds (3) and (4), one of which (3) is synthesized by coupling of 6-methyl-2-benzo[b]thiophenecarboxylic acid (1) with 1-amino-alpha-alpha-cyclopentan carboxylic acid and subsequent cyclization with oxazolone, while the other, compound (4), is obtained from suitable highly selective functionalizations of 4-aminomethylpiperidine (2).

Abstract: New N-hydroxyamides of n-alkyl carboxylic acids omega substituted with suitable tricyclic systems characterised by a central 7-membered ring, having activity as inhibitors of histone deacetylase (HDAC).

Abstract: Described herein are compounds of formula (I) useful as antagonists of tachykinins in general, and in particular of neurokinin A; and the pharmaceutical formulations comprising the compounds of formula (I)

Abstract: Basic monocyclic compounds having general formula (I) useful as NK-2 antagonists are described, processes for their preparation and pharmaceutical compositions containing them are also described.

Abstract: Described herein are compounds of formula (I) useful as antagonists of tachykinins in general, and in particular of neurokinin A; and the pharmaceutical formulations comprising the compounds of formula (I) 1

Abstract: Disclosed are monocyclic compounds containing four bifunctional residues linked together via peptide or pseudopeptide bonds of the general formula (I): having tachykinin receptor antagonist activity. In particular, compounds of formula I are shown to be neurokinin-2 (NK-2) antagonists useful in the treatment or prevention of disorders of the central nervous system, inflammatory diseases, asthma, or pain.

Abstract: This invention relates to novel compounds of general formula (I): ##STR1## and to pharmaceutical compositions containing them.

Abstract: Novel derivatives of 11-carbonyl-6,11-dihydrodibenzo[c,f][1,2,5]thiadiazepine 5,5-dioxide of the general formula ##STR1## wherein R and R.sub.1, which can be different, represent a hydrogen atom or a (C.sub.1 -C.sub.5) alkyl or (C.sub.1 -C.sub.4)hydroxyalkyl group, or R and R.sub.1 together can form a 5-membered and/or 6-membered heterocyclic ring which may contain a further heteroatom,R.sub.2 and R.sub.3, which can be different, represent a hydrogen atom, a (C.sub.1 -C.sub.3)alkoxy, (C.sub.1 -C.sub.3)alkyl, nitro, amino or (C.sub.1 -C.sub.3)alkylamino, halogen, halogeno-alkyl or hydroxyl group,R.sub.4 represents a hydrogen atom or a (C.sub.1 -C.sub.4) alkyl, alkylaryl or (C.sub.1 -C.sub.6)alkylamino group, andn assumes values of 0, 1 or 2, andnon-toxic, pharmaceutically acceptable salts thereof, obtained by addition of acids or alkyl halides.

Abstract: Compounds corresponding to the general formula ##STR1## wherein: R and R1, that may be different, represent a hydrogen atom, a halogen, an alkyl group, an alkoxy radical in which the alkyl group contains one to four carbon atoms, a nitro group, a cyano group, an amino group, an acetamino group, a sulfamidic or N-substituted sulfamidic group; R2 represents a hydrogen atom, a halogen, an alkoxy radical, an alkyl group, a phenyl group, a phenylalkyl group, a phenylalkylene or phenylalkenyl group in which the alkylene or alkenyl radical contains two to four carbon atoms, a nitro group, a cyano group, an amino group, an acetamino group, an N-substituted suylfamidic group; and R3 represents a hydrogen atom, an alkyl group, preferably containing one to three carbon atoms or a cyano group.

Abstract: The invention comprises: a derivative of 1-alkylamine-3-[4(p-alkyloxy-benzamide)phenoxy]-2-propanol of general formula I: ##STR1## where R.sub.1 is a linear or branched alkyl chain with 1 to 8 carbon atoms included, an alkenyl chain with 2 to 8 carbon atoms included, or an arylalkyl chain with 7 to 10 carbon atoms included, and R is a linear or branched alkyl group with 1 to 8 carbon atoms included;a compound as above, in an optically active form;pharmaceutically acceptable, non toxic salts of the above compounds;synthesis processes for obtaining the above compounds; anda pharmaceutical composition based on a compound as defined above.

Abstract: A new compound 3(4-phenyl-1-piperazinio-1-yl)-1,2-propanediol 3(theophyllin-7-yl)-1-propanesulphonate, possesses antitussive action and is therefore usable in therapy. The compound is obtained by treating 3(theophyllin-7-yl)-1-propanesulphonic acid with 3(4-phenylpiperazin-1-yl)-1,2-propanediol in a suitable solvent.